Cytrx Value Stock - Dividend - Research Selection
Market price: 1,39 USD
Cytrx Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-6.140.130|
|Free cash flow||-6.166.032|
|Liabilities & Shareholders equity||12.060.200|
|Diluted shares outstanding||35.266.400|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||52.194.272,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2017-11-01,1.0000/6.0000; 2012-05-16,1.0000/7.0000; 2008-03-07,10000.0000/8616.0000; 1996-02-06,1.0000/4.0000|
Description of the company
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company´s oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company´s tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.